Clinical management update: Evaluation and management of older patients with breast cancer

Journal of the American Geriatrics Society

Volumn 57, Issue SUPPL. 2, 2009, Pages 250-252

  Owusu, Cynthia ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer older update

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; BREAST CANCER; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CARDIOTOXICITY; CELL INVASION; CELL PROLIFERATION; CLINICAL EVALUATION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; GENE EXPRESSION; HUMAN; MEDICAL PRACTICE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

EID: 72049124827     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2009.02504.x     Document Type: Conference Paper

References (18)

1. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 2001 19: 3817 3827.
2. EBCT (Early Breast Cancer Trialists' Collaborative Group). Favorable and unfavorable effects on long-term survival of radiotherapy for early breast cancer: An overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 2000 355: 1757 1770.
3. Hughes KS, Schnaper LA, Berry D et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 2004 351: 971 977.
4. National Comprehensive Cancer Network. Clinical Practice Guidelines in Breast Cancer. Version 1. 2008.
5. Owusu C, Buist DS, Field TS et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 2008 26: 549 555.
6. Partridge AH, LaFountain A, Mayer E et al. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 2008 26: 556 562.
7. Cross M, Dexter TM. Growth factors in development, transformation, and tumorigenesis. Cell 1991 64: 271 280.
8. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987 235: 177 182.
9. Viani GA, Afonso SL, Stefano EJ et al. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: A meta-analysis of published randomized trials. BMC Cancer 2007 7: 153.
10. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005 353: 1673 1684.
11. Lewis JH, Kilgore ML, Goldman DP et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003 21: 1383 1389.
12. Trastuzumab (Herceptin). South San Francisco, CA: Genentech, 2006 (package insert).
13. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004 351: 2817 2826.
14. Fisher B, Jeong JH, Bryant J et al. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: Long-term findings from National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. Lancet 2004 364: 858 868.
15. Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008 26: 721 728.
16. Fisher B, Dignam J, Wolmark N et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997 89: 1673 1682.
17. Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006 24: 3726 3734.
18. NIH Consensus Development Conference statement on the treatment of early-stage breast cancer, 2000 [on-line]. Available at Accessed August 13, 2009.